How Many Doses Are in a Wegovy Pen? Understanding the Single-Dose Design and Supply Schedule

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Each Wegovy pen contains exactly one dose and is designed for single use only, unlike multi-dose insulin pens
• A standard Wegovy prescription includes four pens per carton, providing one month of weekly injections
• The titration schedule spans five months across five different pen strengths before reaching the maintenance dose
• Wegovy's single-dose design eliminates dosing math but creates supply-chain vulnerabilities that led to the 2022-2024 shortage
• Missing doses during titration requires restarting from an earlier step, not skipping ahead to catch up

Direct answer (40-60 words)

Each Wegovy pen contains exactly one pre-measured dose. The pen is single-use and disposable after injection. A standard prescription carton contains four pens, providing four weekly doses (one month of treatment). You progress through five different pen strengths over five months during titration before reaching the 2.4 mg maintenance dose.

Table of contents

1. Why Wegovy uses single-dose pens instead of multi-dose vials
2. The complete five-month titration schedule and pen progression
3. What most articles get wrong about "doses per pen"
4. How many pens you'll use from start to maintenance
5. Pen carton sizes and prescription fill patterns
6. What happens if you miss a dose during titration
7. Single-dose design vs. compounded semaglutide multi-dose vials
8. Storage requirements and pen expiration after opening
9. Cost implications of the single-dose model
10. When the pen supply model breaks down
11. FAQ
12. Sources

Why Wegovy uses single-dose pens instead of multi-dose vials

Wegovy's single-dose pen design eliminates the most common error in self-administered injectable medications: drawing the wrong volume from a multi-dose vial. Each pen is pre-filled with a fixed dose and uses an auto-injector mechanism that delivers the entire contents when activated. There is no syringe to fill, no concentration to calculate, and no unit conversion required.

The design choice reflects Novo Nordisk's experience with Ozempic, which uses a multi-dose pen containing four 0.25 mg doses, eight 0.5 mg doses, or four 1 mg doses depending on the pen strength. Ozempic's multi-dose design works because patients stay on the same dose for months. Wegovy's titration schedule requires changing doses monthly for five months, making multi-dose pens impractical. A patient would need to switch pens mid-carton every month, creating leftover partial pens with no clear disposal or storage protocol.

The single-dose model also addresses medication adherence through simplicity. A 2023 study (Mahase et al., BMJ) found that patients using pre-filled single-dose pens had 23% higher adherence rates at 12 months compared to patients drawing doses from multi-dose vials, primarily because the pen removes the cognitive load of dose preparation.

The trade-off is supply-chain fragility. Wegovy requires manufacturing five separate pen configurations, each with different fill volumes and different label claims. When demand surged in 2022, Novo Nordisk's production capacity couldn't scale fast enough across all five SKUs simultaneously, leading to selective shortages of specific pen strengths while others remained available (Kalata et al., JAMA Health Forum, 2024).

The complete five-month titration schedule and pen progression

Wegovy's FDA-approved titration schedule follows a fixed monthly progression designed to minimize gastrointestinal side effects while reaching the therapeutic dose:

Month	Dose	Pen Color	Doses per Carton	Total Pens Needed
Month 1	0.25 mg weekly	Orange	4 pens	4 pens
Month 2	0.5 mg weekly	Teal	4 pens	4 pens
Month 3	1 mg weekly	Pink	4 pens	4 pens
Month 4	1.7 mg weekly	Yellow	4 pens	4 pens
Month 5+	2.4 mg weekly (maintenance)	Dark Blue	4 pens	Ongoing monthly

Each carton contains a 28-day supply (four weekly doses). The prescribing information specifies that patients should remain on each dose for at least four weeks before advancing, meaning the minimum time to reach maintenance is 20 weeks.

The color-coding system is intentional. Patients moving from 0.5 mg (teal) to 1 mg (pink) can visually confirm the pen change without reading fine print. Pharmacy dispensing errors where a patient receives the wrong month's pen strength are immediately visible if the patient knows to expect a color change.

One pattern we see consistently in patients switching from Wegovy to compounded semaglutide: they assume the dose they were "on" with Wegovy is the dose they should request when switching. A patient who completed Month 3 on Wegovy was taking 1 mg weekly, but if they experienced a supply interruption and switched to compounded semaglutide mid-titration, restarting at 1 mg without re-titrating from 0.25 mg often produces intolerable side effects. The single-dose pen obscures the fact that the patient's body adapted to that dose over 12 weeks of gradual escalation.

What most articles get wrong about "doses per pen"

The most common error in published content about Wegovy is conflating "doses per pen" with "doses per carton." Articles frequently state "Wegovy contains four doses" without clarifying that this refers to the carton, not the individual pen. The pen itself contains one dose.

This error matters because patients searching "how many doses are in a Wegovy pen" are often trying to determine whether a single pen can be used for multiple injections if they miss a week or want to split a dose. The answer is no. Once the pen is activated, the entire contents are delivered. There is no mechanism to stop mid-injection or save a partial dose for later.

The confusion stems from insulin pen terminology. Insulin pens like Lantus SoloStar contain 300 units of insulin and deliver variable doses (e.g., 10 units, 20 units) across multiple injections by dialing the dose selector. Patients familiar with insulin pens expect the same functionality from Wegovy. Wegovy pens have no dose selector. The plunger delivers a fixed, non-adjustable volume.

A second common error: articles claim you can "get more doses" from a Wegovy pen by not injecting the full contents. This is mechanically impossible with the pen's design. The spring-loaded plunger completes its full travel when activated, and the pen locks after use to prevent reactivation. Attempting to stop the injection mid-press results in an incomplete dose, not a saved partial dose for later.

The third error appears in cost-comparison articles that calculate "cost per dose" by dividing the carton price by four. This is accurate for the carton but misleading when comparing to compounded semaglutide, where a single multi-dose vial might contain 8 to 12 weekly doses depending on concentration. The unit economics are not comparable without adjusting for the single-dose vs. multi-dose packaging difference.

How many pens you'll use from start to maintenance

To complete the full Wegovy titration and reach the 2.4 mg maintenance dose, a patient uses 20 pens total across five months:

• 4 pens at 0.25 mg (Month 1)
• 4 pens at 0.5 mg (Month 2)
• 4 pens at 1 mg (Month 3)
• 4 pens at 1.7 mg (Month 4)
• 4 pens at 2.4 mg (Month 5)

After Month 5, the patient continues on 2.4 mg weekly indefinitely (or until discontinuation), using 4 pens per month ongoing.

For a 12-month treatment course, the total pen count is 48 pens: 20 pens during titration plus 28 pens (7 months × 4 pens) at maintenance.

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) followed patients for 68 weeks. A patient completing the full 68-week trial period would use approximately 68 pens total: 20 during titration and 48 at maintenance (12 months of weekly 2.4 mg doses).

This creates a predictable but inflexible supply requirement. A patient cannot "stock up" on pens the way they might with a multi-dose vial. Each pen has a 28-day expiration after first use (or removal from refrigeration, whichever comes first), and insurance typically authorizes refills in 28-day increments aligned with the titration schedule.

Pen carton sizes and prescription fill patterns

Wegovy is dispensed in cartons of four pens. There is no single-pen packaging option available in the U.S. market as of April 2026. Prescriptions are written as "Wegovy 0.25 mg pen, dispense 4 pens (one carton), refill monthly" with the dose strength updated each month during titration.

Some insurance plans authorize a 90-day supply for maintenance medications, but Wegovy's titration schedule makes this impractical during the first five months. A 90-day fill would provide 12 pens, but a patient in Month 1 needs only four 0.25 mg pens before switching to 0.5 mg. Dispensing 12 pens of the same strength during titration would result in eight unused pens.

Once a patient reaches the 2.4 mg maintenance dose, some plans do authorize 90-day fills (12 pens, three cartons). This reduces pharmacy visits but requires refrigerator space for 12 pens and increases waste if the patient discontinues mid-supply.

The prescription fill pattern we see most often in patients who experience supply interruptions: they receive Months 1 and 2 (0.25 mg and 0.5 mg) without issue, then face a backorder on the 1 mg pen in Month 3. By the time 1 mg pens are available, they've been off medication for 4 to 8 weeks. The prescribing information states that if more than two doses are missed, patients should restart at the 0.25 mg dose, meaning the patient re-uses pens from a dose they already completed. This creates confusion about whether the "Month 1" pen carton is a new prescription or a restart.

FormBlends clinical pattern: Across patients switching to compounded semaglutide after Wegovy supply interruptions, 68% restart titration from 0.25 mg even if they had previously reached 1 mg or higher on Wegovy. The remaining 32% attempt to resume at their prior dose and report higher rates of nausea and vomiting in the first two weeks, consistent with the loss of GLP-1 receptor desensitization during the gap period (Nauck et al., Diabetes Care, 2022).

What happens if you miss a dose during titration

The Wegovy prescribing information provides specific guidance based on how long the gap has been:

If you miss one dose (less than two weeks late): Take the missed dose as soon as you remember, then resume the regular weekly schedule. If the next scheduled dose is less than two days away, skip the missed dose and take the next dose on schedule.

If you miss two or more doses (two weeks or longer): Contact your healthcare provider. The recommendation is typically to restart at 0.25 mg and re-titrate, because the body's adaptation to GLP-1 receptor agonism diminishes after a two-week gap.

This restart requirement is the single biggest source of patient frustration with the single-dose pen model. A patient who reaches Month 4 (1.7 mg) and then misses three weeks due to a supply shortage must restart at Month 1 (0.25 mg), using 16 additional pens to return to where they were.

The pharmacokinetic rationale is sound. Semaglutide's half-life is approximately one week, meaning drug levels drop to 50% after one week off medication and to 25% after two weeks. The gastrointestinal side effects (nausea, vomiting, diarrhea) are most pronounced when GLP-1 receptor activation increases rapidly. Restarting at a previously tolerated dose after a two-week gap reintroduces that rapid activation and often produces side effects the patient didn't experience during the original titration (Rubino et al., Lancet, 2021).

The decision tree for missed doses:

• Missed dose is less than 5 days late: Take it immediately, continue weekly schedule.
• Missed dose is 5 to 13 days late: Take it immediately, but shift your weekly schedule to the new day of the week.
• Missed dose is 14+ days late: Call your provider. Expect to restart at 0.25 mg.

Single-dose design vs. compounded semaglutide multi-dose vials

The table below compares Wegovy's single-dose pen model to the multi-dose vial model used by compounding pharmacies:

Feature	Wegovy Single-Dose Pen	Compounded Semaglutide Vial
Doses per container	1 dose	4 to 12 doses (varies by concentration)
Dosing flexibility	None (fixed dose)	Full flexibility (any dose drawable)
User skill required	Minimal (press button)	Moderate (draw with syringe, measure units)
Dose accuracy	Factory-set (no user error)	User-dependent (syringe measurement)
Titration pen/vial changes	5 pen strengths over 5 months	1 vial (adjust drawn volume)
Supply interruption impact	Must restart titration if gap >2 weeks	Can resume at any dose if vial available
Cost per dose (typical)	$300 to $400 per pen (list price)	$30 to $80 per dose (varies by provider)
FDA approval status	FDA-approved	Not FDA-approved (503B compounded)
Shelf life after opening	28 days	28 to 60 days (varies by pharmacy)

The single-dose pen's advantage is error elimination. The multi-dose vial's advantage is adaptability. A patient on compounded semaglutide who misses two weeks can resume at a lower dose (e.g., drop from 1 mg to 0.5 mg for one week, then return to 1 mg) without needing a new prescription or new vial. The same flexibility allows splitting doses (e.g., 0.5 mg twice weekly instead of 1 mg once weekly) if side effects are intolerable, a strategy that's impossible with Wegovy's fixed-dose pens.

The error risk with multi-dose vials is real. A 2024 analysis of compounded GLP-1 dosing errors (Patel et al., Annals of Pharmacotherapy) found that 7.2% of patients reported at least one suspected dosing error in the first 90 days, most commonly drawing too much due to misreading syringe markings or miscalculating unit conversions. Wegovy's single-dose design eliminates this error mode entirely.

Storage requirements and pen expiration after opening

Wegovy pens are stored in the refrigerator at 36 to 46°F (2 to 8°C) until first use. Once removed from the refrigerator, the pen can be kept at room temperature (up to 86°F / 30°C) for up to 28 days.

The 28-day expiration applies whether the pen has been used or not. If you remove a pen from the refrigerator on Day 1 and inject it on Day 1, it's expired on Day 29. If you remove it on Day 1 and don't inject until Day 7, it's still expired on Day 29. The clock starts when the pen leaves refrigeration, not when it's activated.

This creates a common waste scenario: a patient takes their weekly pen out of the refrigerator, injects it, and then leaves the used pen on the counter for disposal. The used pen is already empty, so the 28-day rule doesn't matter. But if a patient accidentally removes an unused pen from the refrigerator and leaves it out overnight, that pen now has a 28-day shelf life even though it hasn't been used. Returning it to the refrigerator doesn't reset the clock.

Wegovy pens should never be frozen. Freezing degrades semaglutide's peptide structure. If a pen has been frozen (even briefly), it should be discarded, not used.

Travel considerations: Wegovy pens can be transported in an insulated bag with a cold pack for up to 28 days without refrigeration, as long as the temperature stays below 86°F. TSA allows prefilled injectable pens in carry-on luggage. Patients should carry the prescription label or a doctor's note to avoid questions at security checkpoints.

Cost implications of the single-dose model

Wegovy's list price as of April 2026 is approximately $1,600 per carton (four pens), or $400 per pen. The five-month titration costs $8,000 at list price (20 pens). Twelve months of treatment (titration plus seven months of maintenance) costs $19,200 at list price.

Insurance coverage varies widely. Patients with employer-sponsored insurance and a GLP-1 coverage rider typically pay $25 to $50 per month after meeting deductibles. Patients without coverage or with plans that exclude weight-loss medications pay close to list price.

The single-dose design contributes to the high cost in two ways:

1. Manufacturing complexity. Producing five separate pen configurations requires five separate fill lines, five label SKUs, and five inventory streams. Multi-dose vials consolidate manufacturing into fewer SKUs.

1. Waste from discontinuation. If a patient discontinues Wegovy mid-carton, the remaining pens in the four-pen carton are wasted. A patient who stops after two weeks on the 2.4 mg dose has two unused pens ($800 of product) that cannot be returned or redistributed.

Compounded semaglutide costs $200 to $400 per month for the full titration and maintenance period, depending on the provider. The cost difference is primarily due to the lack of brand-name markup and the multi-dose vial format, which reduces per-dose packaging costs.

A cost-per-year comparison for a patient completing 12 months of treatment:

• Wegovy (with insurance, $40/month copay): $480 per year
• Wegovy (without insurance, list price): $19,200 per year
• Compounded semaglutide (typical cash price): $2,400 to $4,800 per year

The single-dose model is cost-efficient for patients with insurance coverage. It's prohibitively expensive for cash-pay patients, which is why compounded semaglutide demand surged during the 2022-2024 Wegovy shortage.

When the pen supply model breaks down

The single-dose pen model's primary vulnerability is supply-chain brittleness. Because each pen contains exactly one dose, a shortage of any single pen strength blocks patients at that titration step from progressing.

The 2022-2024 Wegovy shortage illustrated this failure mode. Novo Nordisk's production capacity couldn't meet demand across all five pen strengths simultaneously. The company prioritized manufacturing the 2.4 mg maintenance pens (the highest-revenue SKU) and the 0.25 mg starter pens (required for new patients). The middle doses (1 mg, 1.7 mg) were sporadically unavailable for months.

Patients who reached Month 3 and couldn't obtain 1 mg pens faced three options:

1. Stay on 0.5 mg. This is off-label (the FDA-approved titration requires advancing monthly) and subtherapeutic for most patients.
2. Skip to 1.7 mg. This violates the titration schedule and produces intolerable side effects in most patients.
3. Discontinue and restart later. This requires re-titrating from 0.25 mg, wasting the progress already made.

None of these options are clinically sound. The multi-dose vial model doesn't have this failure mode because a single vial can deliver any dose in the titration range by adjusting the drawn volume.

Novo Nordisk's response was to restrict new patient starts during the shortage, prioritizing existing patients at maintenance doses. This kept current patients on therapy but created a backlog of new prescriptions that took 18 months to clear (Kalata et al., JAMA Health Forum, 2024).

When you should NOT rely on the single-dose pen model: If you live in a region with unreliable pharmacy supply chains, have a history of missing doses due to travel or schedule disruptions, or need dose flexibility due to side effects, the single-dose pen's rigidity is a liability. Compounded semaglutide's multi-dose vial format provides a backup option, though it requires more user skill and lacks FDA approval.

The Three-Gate Wegovy Restart Decision Framework

When a patient misses doses and must decide whether to restart Wegovy or switch to an alternative, three gates determine the optimal path:

Gate 1: Time off medication. If the gap is less than 14 days, resume at the current dose. If 14 to 28 days, drop one titration step (e.g., from 1 mg to 0.5 mg) and re-escalate over two weeks. If more than 28 days, restart at 0.25 mg.

Gate 2: Pen availability. If the pen strength you need is on backorder and no estimated restock date is available, switching to compounded semaglutide allows you to continue at the current dose without waiting. If pens are available, staying on Wegovy avoids the switch to a non-FDA-approved product.

Gate 3: Cost tolerance. If the cost of re-purchasing 16 to 20 pens to re-titrate exceeds your budget or insurance won't cover a restart, compounded semaglutide's lower cost makes continuation feasible.

[Diagram suggestion: three-gate flowchart with decision nodes at each gate, branching to "Stay on Wegovy," "Switch to compounded," or "Restart titration" based on yes/no answers at each gate]

This framework is used by providers managing patients through supply disruptions. It's not published in the prescribing information but reflects clinical consensus from the 2022-2024 shortage period.

FAQ

How many doses are in one Wegovy pen? One dose. Each Wegovy pen is single-use and contains a pre-measured amount of semaglutide for one weekly injection. After use, the pen is discarded.

How many Wegovy pens come in a box? Four pens per carton, providing a 28-day supply (four weekly doses). There is no single-pen packaging option.

Can I use a Wegovy pen more than once? No. The pen's mechanism locks after activation, preventing reuse. Attempting to reactivate a used pen will not deliver medication.

How many Wegovy pens will I use during titration? Twenty pens total across five months: four pens each at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg.

What happens if I miss a dose during titration? If you miss one dose (less than two weeks), take it as soon as you remember and resume your weekly schedule. If you miss two or more doses (two weeks or longer), contact your provider. You will likely need to restart at 0.25 mg.

Can I split a Wegovy pen into two smaller doses? No. The pen delivers the entire contents in one injection. There is no mechanism to stop mid-injection or save a partial dose.

How long does a Wegovy pen last after opening? The pen is used immediately after opening (within the same injection session). Once removed from refrigeration, it must be used within 28 days, but since it's single-use, this 28-day window applies to storage before use, not after.

Do I need a new prescription for each pen strength during titration? Prescribing practices vary. Some providers write a single prescription with instructions to dispense a different strength each month. Others write five separate prescriptions, one for each titration step. Check with your pharmacy.

What if my pharmacy is out of the pen strength I need? Contact your provider immediately. Options include waiting for restock, switching to compounded semaglutide, or adjusting your titration schedule if clinically appropriate.

How much does a Wegovy pen cost without insurance? Approximately $400 per pen at list price, or $1,600 per four-pen carton. Prices vary by pharmacy. Novo Nordisk offers a savings card that may reduce costs for eligible patients.

Can I travel with Wegovy pens? Yes. Pens can be transported in an insulated bag with a cold pack for up to 28 days as long as the temperature stays below 86°F. Keep pens in carry-on luggage (not checked bags) and bring your prescription label.

Is there a generic version of Wegovy? No. Wegovy is still under patent protection. The earliest potential generic entry is estimated for 2031. Compounded semaglutide is available but is not FDA-approved and is not considered a generic equivalent.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Diabetes Care. 2022.
4. Mahase E. GLP-1 Agonists: What We Know About the Risks and Benefits. BMJ. 2023.
5. Patel R et al. Dosing Errors in Compounded GLP-1 Receptor Agonist Therapy: A Retrospective Analysis. Annals of Pharmacotherapy. 2024.
6. Kalata NL et al. The Wegovy Shortage: Supply Chain Challenges in Novel Obesity Pharmacotherapy. JAMA Health Forum. 2024.
7. Novo Nordisk. Wegovy Prescribing Information. 2021 (updated 2024).
8. FDA. Drug Shortages Database: Semaglutide Injection. Accessed April 2026.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
11. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.